Estados Unidos · Plataformas y datos · Finviz

Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance

Publicado por Finviz · Estados Unidos hace 9 h

Few biotech earnings reports hinge on a single number the way this one does. Wall Street expects Zymeworks to post roughly $249.7 million in third-quarter revenue when it reports…

Leer el artículo completo en Finviz Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finviz.com)

Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance

También te puede interesar

MSA Safety beats top-line estimates; reaffirms FY26 outlook

SLB (NYSE:SLB) Stock Breaks Below 50 Day Moving Average After Insider Selling

Australian, Chinese airline stocks jump as oil prices plunge more than 7%

Stock market after midterm elections: What S&P 500 history shows

GraniteShares 3x Short Palantir Daily ETC 3SPA ETF Analysis

S&P 500, Nasdaq Drop As Capex Concerns Grip Tech Investors, Outweighing US-Iran Diplomacy Hope — ORCL, META, PLTR, AAPL In Focus

Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance

Compartir

También te puede interesar

MSA Safety beats top-line estimates; reaffirms FY26 outlook

SLB (NYSE:SLB) Stock Breaks Below 50 Day Moving Average After Insider Selling

Australian, Chinese airline stocks jump as oil prices plunge more than 7%

Stock market after midterm elections: What S&P 500 history shows

GraniteShares 3x Short Palantir Daily ETC 3SPA ETF Analysis

S&P 500, Nasdaq Drop As Capex Concerns Grip Tech Investors, Outweighing US-Iran Diplomacy Hope — ORCL, META, PLTR, AAPL In Focus